Mikel P. Moyer

6.5k total citations · 2 hit papers
28 papers, 2.5k citations indexed

About

Mikel P. Moyer is a scholar working on Molecular Biology, Hematology and Organic Chemistry. According to data from OpenAlex, Mikel P. Moyer has authored 28 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 5 papers in Hematology and 4 papers in Organic Chemistry. Recurrent topics in Mikel P. Moyer's work include Epigenetics and DNA Methylation (19 papers), Cancer-related gene regulation (18 papers) and RNA modifications and cancer (6 papers). Mikel P. Moyer is often cited by papers focused on Epigenetics and DNA Methylation (19 papers), Cancer-related gene regulation (18 papers) and RNA modifications and cancer (6 papers). Mikel P. Moyer collaborates with scholars based in United States, Canada and United Kingdom. Mikel P. Moyer's co-authors include Margaret Porter Scott, Robert A. Copeland, Roy M. Pollock, Richard Chesworth, Victoria M. Richon, Christine R. Klaus, Alejandra Raimondi, Tim J. Wigle, Christina J. Allain and Kevin W. Kuntz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and PLoS ONE.

In The Last Decade

Mikel P. Moyer

28 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

2013 581 citations Sarah K. Knutson, Natalie M. Warholic et al. profile →
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mikel P. Moyer United States	19	2.1k	371	267	193	141	28	2.5k
Stephen C. Cosenza United States	23	1.1k 0.5×	460 1.2×	296 1.1×	571 3.0×	111 0.8×	55	2.0k
Frank Bennett United States	23	1.2k 0.6×	397 1.1×	135 0.5×	272 1.4×	93 0.7×	75	2.0k
Kenna Anderes United States	18	1.8k 0.9×	210 0.6×	94 0.4×	576 3.0×	218 1.5×	46	2.3k
David M. Ryckman United States	18	1.3k 0.6×	423 1.1×	75 0.3×	413 2.1×	137 1.0×	31	1.8k
Juerg Zimmermann Switzerland	7	716 0.3×	581 1.6×	309 1.2×	356 1.8×	80 0.6×	10	1.6k
Giorgio Caravatti Switzerland	26	1.5k 0.7×	660 1.8×	206 0.8×	713 3.7×	131 0.9×	45	2.3k
Sanna Herrgård United States	5	1.3k 0.6×	183 0.5×	141 0.5×	339 1.8×	68 0.5×	6	1.8k
Steven K. Davidsen United States	31	1.9k 0.9×	1000 2.7×	209 0.8×	702 3.6×	275 2.0×	80	3.0k
Michael J. Munchhof United States	16	938 0.5×	413 1.1×	267 1.0×	340 1.8×	117 0.8×	30	1.6k
Kevin Kish United States	20	930 0.5×	381 1.0×	433 1.6×	265 1.4×	61 0.4×	38	2.0k

Countries citing papers authored by Mikel P. Moyer

Since Specialization

Citations

This map shows the geographic impact of Mikel P. Moyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikel P. Moyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikel P. Moyer more than expected).

Fields of papers citing papers by Mikel P. Moyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikel P. Moyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikel P. Moyer. The network helps show where Mikel P. Moyer may publish in the future.

Co-authorship network of co-authors of Mikel P. Moyer

This figure shows the co-authorship network connecting the top 25 collaborators of Mikel P. Moyer. A scholar is included among the top collaborators of Mikel P. Moyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikel P. Moyer. Mikel P. Moyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waters, Nigel J., Sherri Smith, Edward J. Olhava, et al.. (2015). Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human. Cancer Chemotherapy and Pharmacology. 77(1). 43–62. 23 indexed citations

Mitchell, Lorna H., Allison E. Drew, Scott Ribich, et al.. (2015). Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Medicinal Chemistry Letters. 6(6). 655–659. 95 indexed citations

Campbell, John E., Kevin W. Kuntz, Sarah K. Knutson, et al.. (2015). EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Medicinal Chemistry Letters. 6(5). 491–495. 94 indexed citations

Duncan, Kenneth W., Nathalie Rioux, P. Ann Boriack‐Sjodin, et al.. (2015). Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Medicinal Chemistry Letters. 7(2). 162–166. 103 indexed citations

Wigle, Tim J., Kerren K. Swinger, John E. Campbell, et al.. (2015). A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening. SLAS DISCOVERY. 20(6). 810–820. 31 indexed citations

Rioux, Nathalie, Kenneth W. Duncan, Xiu‐Sheng Miao, et al.. (2015). Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. Xenobiotica. 46(3). 268–277. 16 indexed citations

Rioux, Nathalie, Lorna H. Mitchell, Philip R. Tiller, et al.. (2015). Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652. Drug Metabolism and Disposition. 43(7). 936–943. 5 indexed citations

Boriack‐Sjodin, P. Ann, Lei Jin, Suzanne L. Jacques, et al.. (2015). Structural Insights into Ternary Complex Formation of Human CARM1 with Various Substrates. ACS Chemical Biology. 11(3). 763–771. 32 indexed citations

Klaus, Christine R., Danielle Johnston, J. Joshua Smith, et al.. (2014). DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells. Journal of Pharmacology and Experimental Therapeutics. 350(3). 646–656. 96 indexed citations

10.

Knutson, Sarah K., Natalie M. Warholic, L. Danielle Johnston, et al.. (2014). Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS ONE. 9(12). e111840–e111840. 55 indexed citations

11.

Basavapathruni, Aravind, Edward J. Olhava, Scott R. Daigle, et al.. (2014). Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor. Biopharmaceutics & Drug Disposition. 35(4). 237–252. 64 indexed citations

12.

Daigle, Scott R., Edward J. Olhava, Aravind Basavapathruni, et al.. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 122(6). 1017–1025. 546 indexed citations breakdown →

13.

Hallenbeck, Kenneth K., Christina R. Majer, Lei Jin, et al.. (2013). Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys27 methylation by human polycomb repressive complex 2 and vSET. Biochemical Journal. 453(2). 241–247. 5 indexed citations

14.

Johnston, L. Danielle, Sarah K. Knutson, Natalie M. Warholic, et al.. (2013). EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models. Blood. 122(21). 4416–4416. 5 indexed citations

15.

Majer, Christina R., Lei Jin, Margaret Porter Scott, et al.. (2012). A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients. FEBS Letters. 586(19). 3448–3451. 116 indexed citations

16.

Basavapathruni, Aravind, Lei Jin, Scott R. Daigle, et al.. (2012). Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L. Chemical Biology & Drug Design. 80(6). 971–980. 114 indexed citations

17.

Pollock, Roy M., Scott R. Daigle, Aravind Basavapathruni, et al.. (2012). Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia.. Blood. 120(21). 2379–2379. 3 indexed citations

18.

Copeland, Robert A., Aravind Basavapathruni, Mikel P. Moyer, & Margaret Porter Scott. (2011). Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Analytical Biochemistry. 416(2). 206–210. 82 indexed citations

19.

Moyer, Mikel P., Frederick Weber, & Jonathan Groß. (1992). Structure-activity relationships of imidazo[4,5-f]quinoline partial structures and analogs. Discovery of pyrazolo[3,4-f]quinoline derivatives as potent immunostimulants. Journal of Medicinal Chemistry. 35(24). 4595–4601. 20 indexed citations

20.

Moyer, Mikel P., Paul L. Feldman, & Henry Rapoport. (1985). Intramolecular nitrogen-hydrogen, oxygen-hydrogen and sulfur-hydrogen insertion reactions. Synthesis of heterocycles from .alpha.-diazo .beta.-keto esters. The Journal of Organic Chemistry. 50(25). 5223–5230. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact